# Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

> **NCT02226172** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 21 (actual)

## Conditions studied

- Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

## Interventions

- **DRUG:** Glasdegib (PF-04449913)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02226172
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10-06
- **Primary completion:** 2016-12-14
- **Final completion:** 2018-01-31
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2019-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02226172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02226172, "Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02226172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*